Not only is shareholder activism expected to keep pace in 2023, activist campaigns are moving beyond the traditional playbook. And with activists often spending months formulating a plan before approaching corporations, it’s critical for companies to level the playing field by proactively assessing business vulnerabilities. Michal Katz, Head of Investment & Corporate Banking, discusses the key strategies and appropriate mechanisms for successfully mounting an activist response plan.

The Federal Reserve recently launched a new cashless transfer system that could disrupt the debit market and, in turn, the prospects for Fintech companies. But the impact of this new system will vary depending on how companies are positioned, says Dan Dolev, Senior Fintech Equity Research Analyst.

As AI continues to evolve, the semiconductor industry is one of many fields where investors are seeing immense opportunities and benefits from the technology. Senior Semiconductors and Automotive Technologies Analyst Vijay Rakesh examines the AI technology landscape and what this means for the industry.

When will the IPO markets reopen? Few are better placed to answer this question than Lise Buyer, founder of IPO advisory firm, Class V Group.

AI was at the heart of conversations at the 2023 Fortune Brainstorm Tech Conference. Optimism around this massive tech innovation was plentiful, tempered by the need for regulation, governance and guardrails for this unchartered opportunity. Excitement and enthusiasm were also high around investments, as last year’s market uncertainty eases and the IPO market shows signs of returning.

With a general slowdown in M&A and Capital Markets activity, pharma and biotech are leading the charge with large announced deals, successful acquisition financings and evidence of green shoots seen in the equity capital markets. Hear from our experts on what is driving the sector activity and what we expect for the remainder of the year.

An increasing number of companies are developing treatments for neurodegenerative disorders and their symptoms – many of which are showing promising data. The positive outlook could be an emerging opportunity for investors to target smaller drug makers. Graig Suvannavejh, Senior US Healthcare Equity Research Analyst examines how the new age of neuro drug development is creating a major pathway for investors.

Members of Mizuho's Biotech, Healthcare, and REITs Equity Research teams are back for another edition of Mizuho Collaborates, where they discuss the latest developments at the intersection of life sciences and real estate.